South Plainfield, NJ - PTC Therapeutics, Inc. announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates. The program, in its inaugural year, will focus on Duchenne muscular dystrophy (DMD).
"From the time PTC was founded, patient organizations have been valuable partners to us and have played important roles in our research and development programs. We are excited to support these groups and enable them to use their creativity and experience to raise awareness and make a difference for the DMD community," stated Stuart Peltz, Ph.D., CEO of PTC Therapeutics, Inc.
The program is aimed at improving the diagnosis and treatment of DMD patients, increasing the visibility of this devastating rare disorder, and educating the general public and healthcare professionals, as well as identifying and fostering the next generation of DMD patient advocates. Five one-year awards of up to $30,000 each will be given to the most creative, feasible and sustainable proposals identified by a panel of judges. The deadline for submission of proposals is June 22, 2015 and awards will be announced on World Duchenne Awareness Day, on September 7th.
Mary Frances Harmon, who recently joined PTC and will be Global Head of Patient Advocacy, noted "I'm proud to be part of the PTC team. The STRIVE awards program underscores our commitment to advocacy in the rare disease community and demonstrates the importance of increasing awareness and education about rare diseases around the world. I look forward to seeing the great ideas coming forward and working with the organizations to advance the initiatives selected."
For more information, please visit the STRIVE Awards Program's website at: www.ptcbio.com/strive
The program is aimed at improving the diagnosis and treatment of DMD patients, increasing the visibility of this devastating rare disorder, and educating the general public and healthcare professionals, as well as identifying and fostering the next generation of DMD patient advocates. Five one-year awards of up to $30,000 each will be given to the most creative, feasible and sustainable proposals identified by a panel of judges. The deadline for submission of proposals is June 22, 2015 and awards will be announced on World Duchenne Awareness Day, on September 7th.
Mary Frances Harmon, who recently joined PTC and will be Global Head of Patient Advocacy, noted "I'm proud to be part of the PTC team. The STRIVE awards program underscores our commitment to advocacy in the rare disease community and demonstrates the importance of increasing awareness and education about rare diseases around the world. I look forward to seeing the great ideas coming forward and working with the organizations to advance the initiatives selected."
For more information, please visit the STRIVE Awards Program's website at: www.ptcbio.com/strive
